▼ 0.50%
prev close
Icon is a global contract research organization that provides outsourced clinical development services to pharmaceutical and biotechnology firms. Icon supports clients across late-stage clinical trials through the regulatory approval process and postmarket studies. Icon's services include clinical trial management, patient recruitment, data analytics, laboratory services, and regulatory consulting. With more than 40,000 employees operating in over 50 countries, the company partners with life sciences firms to run clinical trials and bring new drugs to market.
Congressional Trades
2
All tracked trades
Members Trading
2
Unique members
Net Activity
-2
0 buys · 2 sells
Members Who Traded This Stock
2 trade events
| Date | Member | Stock | Type | Amount | Filed | Signal |
|---|---|---|---|---|---|---|
| 2024-09-04 | ICLRICON plc - Ordinary Shares | Sell | $1,001 - $15,000 | 635d ago | — | |
| 2023-01-31 | ICLRICON plc - Ordinary Shares | Sell | $1,001 - $15,000 | 1205d ago | — |
2024-09-04
John James
ICLR
Amount
$1,001 - $15,000
Filed
635d ago
2023-01-31
Kevin Hern
ICLR
Amount
$1,001 - $15,000
Filed
1205d ago
Recent News
Powered by Polygon.io
Clinical Trial Data Visualization Research Report 2026: $1.82 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F
eCOA, eSource and Clinical Trials Research Report 2026: $81.46 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F
ICLR SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
FDA Grants Breakthrough Status To Johnson & Johnson's Cancer Drug For Advanced Head and Neck Cancer
Clinical Trials Support Software Solutions in a $34.15B Trial Economy by 2035
Trade Timeline
Congressional activity, newest first
John James
2024-09-04 · Sale
$1,001 - $15,000
Kevin Hern
2023-01-31 · Sale
$1,001 - $15,000